<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1078">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521322</url>
  </required_header>
  <id_info>
    <org_study_id>CEMIC</org_study_id>
    <nct_id>NCT04521322</nct_id>
  </id_info>
  <brief_title>Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease</brief_title>
  <acronym>CARR-COV-02</acronym>
  <official_title>Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariel Dogliotti</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronaviruses are enveloped viruses with an RNA genome. Carrageenans are sulfate
      polysaccharides synthesized by red algae. Studies conducted in adults and children with the
      common cold showed the effectiveness of the use of Carrageenan in nasal spray.

      For decades, the antiviral action of Carrageenans has been described in numerous studies with
      different viruses that infect humans: herpes viruses types 1 and 2, human immunodeficiency
      virus, human papillomavirus, H1N1 influenza virus, dengue virus, rhinovirus, hepatitis A
      virus, and enteroviruses. Studies on the dynamics of COVID-19 disease show an intense and
      rapid pharyngeal multiplication in the first 3-5 days of the onset of symptoms, prior to the
      onset of pulmonary disease.

      Finally, this molecule has shown a viricidal effect against SARS-Cov2 in vitro. All this
      underscores the potential value of a therapy that inhibits the virus in the rhinopharynx.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled trial assessing the use a
      nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 disease in
      health-workers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 24, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomized, double blind compared vs placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>diagnose of COVID19 disease</measure>
    <time_frame>28 days</time_frame>
    <description>COVID 19 disease will be defined for clinical diagnose and positive Polymerase Chain Reaction test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression to a more severe disease state, defined as need for oxygen therapy.</measure>
    <time_frame>28 days</time_frame>
    <description>number of subjects who develop severe COVID19 disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lasting of disease</measure>
    <time_frame>28 days</time_frame>
    <description>number of days with clinical symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of COVID-19 disease onset in the first week after treatment</measure>
    <time_frame>1 week after finishing treatment</time_frame>
    <description>number of subjects who develop the disease within one week after finishing treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants in this arm will receive a nasal spray with placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive a nasal spray with Iota-Carrageenan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iota-Carrageenan</intervention_name>
    <description>Participants will received a nasal spray with Iota-Carrageenan or placebo 4 times a day during 21 days</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  physician, nurses, and physical therapist who usually attend hospitalized COVID19
             patients.

          -  No more than 48 hours since he/she assisted a COVID-19 patient

          -  Able to understand and give written informed consent

        Exclusion Criteria:

          -  Participation in any other clinical trial of an experimental treatment for COVID-19

          -  Not having a cell phone with WhatsApp for remote monitoring

          -  Hypersensitivity or known allergy to any component of the product

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Figueroa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Instituto Milstein-CONICET</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mónica Lombardo, MD</last_name>
    <phone>005491141763599</phone>
    <email>mlombardo@nobeltri.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Valentini, MD</last_name>
    <phone>005491162036790</phone>
    <email>deptomedicina2@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>centro de educación médica e investigaciones clinicas (CEMIC)</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>1425</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mónica Lombardo, MD</last_name>
      <phone>541152990600</phone>
      <email>mlombardo@nobeltri.com</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo c Valentini</last_name>
      <phone>+541152990600</phone>
      <email>rvalentini@cemic.edu.ar</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno</investigator_affiliation>
    <investigator_full_name>Ariel Dogliotti</investigator_full_name>
    <investigator_title>PHYSICIAN</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

